German HTA Body Says Well Done On Immuno-Oncology, But Where Are Dementia Breakthroughs?
Germany’s health technology appraisal institute, IQWiG, says that oncology drugs take up more of its time than treatments for any other conditions. And while it welcomes advances in immuno-oncology, it wants to see breakthroughs in other disease areas too.
You may also be interested in...
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.